Edwards Lifesciences Corporation
EW
$76.04
$0.911.21%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 385.60M | 3.07B | 366.30M | 351.90M | 369.90M |
| Total Depreciation and Amortization | 42.60M | 34.50M | 39.60M | 38.50M | 36.70M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -92.60M | -3.44B | -9.40M | 10.90M | -53.90M |
| Change in Net Operating Assets | -463.10M | 683.60M | -25.00M | -454.80M | -216.10M |
| Cash from Operations | -127.50M | 351.80M | 371.50M | -53.50M | 136.60M |
| Capital Expenditure | -49.80M | -51.90M | -85.40M | -65.30M | -88.30M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -298.20M | -763.60M | -- | -- | 46.00M |
| Divestitures | 0.00 | 3.93B | -- | -- | -- |
| Other Investing Activities | -228.70M | -410.20M | 210.20M | 128.40M | 56.40M |
| Cash from Investing | -576.70M | 2.70B | 124.80M | 63.10M | 14.10M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 28.60M | 34.50M | 54.30M | 62.10M | 33.20M |
| Repurchase of Common Stock | -100.00K | -1.00B | -158.10M | -200.00K | -448.40M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00K | -10.20M | 7.20M | -200.00K | 2.00M |
| Cash from Financing | 28.60M | -976.70M | -96.60M | 61.70M | -413.20M |
| Foreign Exchange rate Adjustments | 51.00M | -51.50M | 29.40M | 9.70M | -3.40M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -624.60M | 2.03B | 429.10M | 81.00M | -265.90M |